{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037346","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.558559+00:00","generated_at":"2026-06-08T16:55:39.816535+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lyell Immunopharma Q3 net loss $50.9M; workforce cut 25%; cash runway to 2027","bullets":["Net loss $50.9M vs $70.3M YoY; non-GAAP net loss $43.0M (flat YoY).","Cash, equivalents and securities $598.2M; company expects funding operations into 2027.","Workforce reduction ~25%; CMO Tina Albertson departing; focus on clinical candidates LYL797 and LYL845.","Initial clinical data for LYL797 in 1H2024; LYL845 data in 2024; LYL119 IND expected 1H2024.","R&D expenses $43.8M (+5% YoY); G&A $15.5M (-41% YoY); no revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037346","json":"https://secwatch.observer/filing/0001628280-23-037346.json","markdown":"https://secwatch.observer/filing/0001628280-23-037346.md","text":"https://secwatch.observer/filing/0001628280-23-037346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/0001628280-23-037346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/lyel-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:55:39.816535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18a832d78a475d2c3d6e540daf96a53977129685","claim":"Lyell Immunopharma, Inc. reported the third quarter ended September 30, 2023 results: revenue approximately zero, net income $50.9 million.","evidence_excerpt":"Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/0001628280-23-037346-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"approximately zero"},{"label":"Net income","value":"$50.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}